Brokerages Set Avalyn Pharma Inc. (NASDAQ:AVLN) PT at $59.00

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN) have been assigned an average recommendation of “Buy” from the five research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $59.00.

Several research analysts have recently issued reports on the company. Zacks Research upgraded Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th. Wall Street Zen raised Avalyn Pharma to a “hold” rating in a research note on Saturday, May 9th. Morgan Stanley assumed coverage on Avalyn Pharma in a report on Tuesday, May 26th. They set an “overweight” rating and a $53.00 target price on the stock. Guggenheim began coverage on Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $80.00 target price for the company. Finally, Jefferies Financial Group began coverage on Avalyn Pharma in a research note on Monday, May 25th. They issued a “buy” rating and a $52.00 price target for the company.

Insider Buying and Selling

In other news, Director Jill Carroll acquired 277,778 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was purchased at an average price of $18.00 per share, for a total transaction of $5,000,004.00. Following the completion of the acquisition, the director owned 2,186,562 shares in the company, valued at $39,358,116. This trade represents a 14.55% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the stock in a transaction on Friday, May 1st. The stock was purchased at an average cost of $18.00 per share, with a total value of $9,999,990.00. Following the purchase, the insider directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This represents a 34.06% increase in their position. The disclosure for this purchase is available in the SEC filing.

Avalyn Pharma Price Performance

Shares of NASDAQ AVLN opened at $28.63 on Friday. Avalyn Pharma has a fifty-two week low of $24.15 and a fifty-two week high of $33.32. The firm has a market capitalization of $1.27 billion and a price-to-earnings ratio of -1.31. The firm has a 50 day simple moving average of $28.86.

Avalyn Pharma (NASDAQ:AVLN) last released its earnings results on Wednesday, June 3rd. The company reported ($21.83) EPS for the quarter, missing analysts’ consensus estimates of ($16.38) by ($5.45).

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.